Bank of America GLP-1 Coverage Spending
Analysis based on 6 articles · First reported Aug 05, 2026 · Last updated Aug 09, 2026
The announcement underscores the growing financial burden of GLP-1 drugs on corporate healthcare budgets, potentially influencing employer coverage decisions and drug pricing negotiations. It also highlights the expanding market for obesity treatments, benefiting manufacturers like Eli Lilly and Novo Nordisk while pressuring employers' healthcare costs.
Bank of America CEO Brian Moynihan announced that the bank spends over $250 million annually on GLP-1 weight-loss medications for its approximately 211,000 employees, up from zero four or five years ago. This spending represents about 13% of the bank's total annual healthcare expenditure of over $2 billion. The bank combines medication coverage with health coaching to support weight management and lifestyle changes. Moynihan cited emerging clinical evidence of cardiovascular benefits and described the investment as worthwhile despite acknowledging that some employees may leave before long-term savings materialize. The announcement highlights a broader trend among U.S. employers grappling with rising GLP-1 costs. According to a July survey by the International Foundation of Employee Benefit Plans, 36% of employers cover GLP-1s for both diabetes and weight loss, and the drugs accounted for 11.4% of annual claims in 2026, up from 6.9% in 2023. Drugmakers Eli Lilly and Company and Novo Nordisk are actively expanding employer coverage programs, with Lilly introducing a discounted Zepbound program at $449 per month.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard